Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The American Association for the Study of Liver Diseases: A history of the first 10 years and its presidents.

Hepatology (Baltimore, Md.)·2022
Same author

Endovascular repair of delayed traumatic aortocaval fistula.

Journal of vascular surgery cases and innovative techniques·2019
Same author

Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy.

Drug design, development and therapy·2019
Same author

Role of echocardiography in managing acute pulmonary embolism.

Heart (British Cardiac Society)·2019
Same author

Detection of Left Ventricular Hypertrophy Using Bayesian Additive Regression Trees: The MESA.

Journal of the American Heart Association·2019
Same author

Of best intentions and best practices: thinking beyond guidelines.

Heart (British Cardiac Society)·2019

Related Experiment Video

Updated: May 14, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Future therapies for chronic hepatitis C.

Noura M Dabbouseh1, Donald M Jensen

  • 1Department of Medicine, Section of Gastroenterology, Hepatology and Nutrition, University of Chicago Medical Center, 5841 South Maryland Avenue, MC7120, Chicago, IL 60637, USA.

Nature Reviews. Gastroenterology & Hepatology
|February 20, 2013
PubMed
Summary

Recent advancements in hepatitis C (HCV) therapy, including direct-acting antivirals, offer improved treatment options. New agents aim for safe, effective, and accessible hepatitis C cures, especially for the baby boomer generation.

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Related Experiment Videos

Last Updated: May 14, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Hepatitis C virus (HCV) therapy saw limited progress for a decade.
  • The 2011 approval of protease inhibitors marked a turning point, improving response rates.
  • Despite progress, there is a continued need for more potent and tolerable HCV treatments.

Purpose of the Study:

  • To review recent developments in hepatitis C therapy.
  • To discuss the potential impact of new therapeutic agents on patient care.
  • To highlight the evolving landscape of direct-acting antivirals and other novel treatments.

Main Methods:

  • Review of recent scientific literature and clinical trial data.
  • Analysis of the current and emerging hepatitis C treatment pipeline.
  • Examination of the projected impact on patient populations, including baby boomers.

Main Results:

  • The HCV therapy pipeline is rapidly expanding with direct-acting antivirals and novel agents.
  • New treatments promise enhanced potency and tolerability compared to older regimens.
  • Increased diagnosis rates are expected in the baby boomer population, necessitating effective therapies.

Conclusions:

  • The evolution of HCV therapy is moving towards safer, simpler, and highly effective treatment paradigms.
  • New agents are crucial for managing the increasing number of diagnosed and at-risk patients.
  • These advancements will significantly influence the delivery of care for hepatitis C infections.